Coverart for item
The Resource CNS clinical trials : suicidality and data collection : workshop summary, Sarah Hanson, Miriam Davis, and Bruce Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Institute of Medicine of the National Academies, (electronic resource)

CNS clinical trials : suicidality and data collection : workshop summary, Sarah Hanson, Miriam Davis, and Bruce Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Institute of Medicine of the National Academies, (electronic resource)

Label
CNS clinical trials : suicidality and data collection : workshop summary
Title
CNS clinical trials
Title remainder
suicidality and data collection : workshop summary
Statement of responsibility
Sarah Hanson, Miriam Davis, and Bruce Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Institute of Medicine of the National Academies
Title variation
Central nervous system clinical trials
Contributor
Subject
Language
eng
Summary
  • "The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future."--Publisher's description
  • "The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future."--Publisher's description
  • "The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future."--Publisher's description
  • "The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future."--Publisher's description
Cataloging source
YDXCP
LC call number
RC569
LC item number
.C537 2010
NLM call number
  • 2011 C-623
  • HV 6543
http://library.link/vocab/relatedWorkOrContributorDate
1980-
http://library.link/vocab/relatedWorkOrContributorName
  • Hanson, Sarah L.
  • Davis, Miriam
  • Altevogt, Bruce M
  • Institute of Medicine (U.S.)
  • National Academies Press (U.S.)
http://library.link/vocab/subjectName
  • Suicide
  • Clinical Trials as Topic
  • Mental Disorders
  • United States
Label
CNS clinical trials : suicidality and data collection : workshop summary, Sarah Hanson, Miriam Davis, and Bruce Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Institute of Medicine of the National Academies, (electronic resource)
Instantiates
Publication
Bibliography note
Includes bibliographical references (p. 43-49)
Contents
  • Perspectives from the FDA, academia, and patients -- Data collection and optimization -- Data analysis -- Partnerships, opportunities, collaboration
  • Perspectives from the FDA, academia, and patients -- Data collection and optimization -- Data analysis -- Partnerships, opportunities, collaboration
  • Perspectives from the FDA, academia, and patients -- Data collection and optimization -- Data analysis -- Partnerships, opportunities, collaboration
  • Perspectives from the FDA, academia, and patients -- Data collection and optimization -- Data analysis -- Partnerships, opportunities, collaboration
Control code
OCM1bookssj0000467759
Dimensions
unknown
Isbn
9780309148832
Specific material designation
remote
System control number
(WaSeSS)bookssj0000467759
Label
CNS clinical trials : suicidality and data collection : workshop summary, Sarah Hanson, Miriam Davis, and Bruce Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Institute of Medicine of the National Academies, (electronic resource)
Publication
Bibliography note
Includes bibliographical references (p. 43-49)
Contents
  • Perspectives from the FDA, academia, and patients -- Data collection and optimization -- Data analysis -- Partnerships, opportunities, collaboration
  • Perspectives from the FDA, academia, and patients -- Data collection and optimization -- Data analysis -- Partnerships, opportunities, collaboration
  • Perspectives from the FDA, academia, and patients -- Data collection and optimization -- Data analysis -- Partnerships, opportunities, collaboration
  • Perspectives from the FDA, academia, and patients -- Data collection and optimization -- Data analysis -- Partnerships, opportunities, collaboration
Control code
OCM1bookssj0000467759
Dimensions
unknown
Isbn
9780309148832
Specific material designation
remote
System control number
(WaSeSS)bookssj0000467759

Library Locations

    • Ellis LibraryBorrow it
      1020 Lowry Street, Columbia, MO, 65201, US
      38.944491 -92.326012
Processing Feedback ...